Form 4: Gilead CEO O'Day Exercises RSUs, Sells Shares for Tax

Gilead Sciences Chairman & CEO Daniel P. O'Day exercised 10,426 restricted stock units and sold 4,931 shares of common stock to cover tax liabilities.

Summary

• Daniel P. O'Day, Chairman & CEO of Gilead Sciences, Inc., reported transactions involving the company's common stock.
• On December 10, 2025, O'Day acquired 10,426 shares of common stock through the exercise/conversion of restricted stock units (RSUs).
• Concurrently, O'Day disposed of 4,931 shares of common stock at a price of $121.34 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, O'Day directly beneficially owns 576,698 shares of common stock.
• O'Day also holds 88,070 restricted stock units, which represent the contingent right to receive one share of common stock each.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and tax-related sale) which are neutral in sentiment. It does not indicate any significant positive or negative operational or financial news.

Positives

• The exercise of restricted stock units indicates a vesting event, which is a normal part of executive compensation and aligns management's interests with shareholders.

Negatives

• A portion of the acquired shares (4,931 shares) was sold to cover tax liabilities, which is a common practice but represents a reduction in direct ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the vesting schedule of the restricted stock units.

Industry Context

This Form 4 filing details a routine insider transaction for Gilead Sciences' CEO, which is common practice in the biotechnology and pharmaceutical industry for executive compensation and tax management. It does not provide broader industry insights.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and tax planning, with minimal direct impact on existing shareholders. The sale for tax purposes slightly reduces the CEO's direct ownership but is offset by the initial RSU conversion.
• Employees: No direct impact on employees.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders.

Next Steps

• The remaining restricted stock units (88,070) will continue to vest, with 25% vesting on the first anniversary of the grant date, and the balance vesting 6.25% quarterly thereafter until fully vested.

Key Dates

Keywords

Gilead Sciences, GILD, Daniel O'Day, Insider Trading, Form 4, Restricted Stock Units, RSU, Stock Sale, CEO, Director, Biotechnology, Pharmaceuticals